Saturday 17 October 2026
Export OGN’s income statement to Excel — free account
Organon & Co.
OGN Healthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
13.76
0.00
0.00%
Follow OGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
5.53 | 9.96 | 6.37 | 17.14 |
P/S ratio |
0.44 | 0.30 | 0.25 | 0.58 | |
P/FCF ratio |
4.45 | 4.48 | 2.79 | 7.66 | |
P/Operating CF |
10.52 | 13.20 | 6.93 | 33.23 | |
P/B ratio |
3.06 | 2.47 | 1.73 | 3.53 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.74 | 1.60 | 1.46 | 1.79 | |
EV/EBITDA |
7.07 | 6.92 | 6.33 | 7.78 | |
EV/Operating CF |
11.52 | 14.19 | 10.60 | 14.89 | |
EV/FCF |
17.52 | 23.93 | 16.09 | 23.66 | |
Quick Ratio |
0.80 | 0.80 | 1.00 | 1.00 | |
Current Ratio |
1.75 | 1.82 | 1.97 | 1.95 | |
Net Debt/EBITDA |
19.51 | 30.45 | 23.59 | 18.06 | |
Debt/Assets |
65.14% | 67.18% | 65.94% | 64.90% | |
Debt/Equity |
9.74 | 11.49 | 9.49 | 8.50 | |
Asset Turnover |
0.48 | 0.48 | 0.47 | 0.46 | |
Operating CF/Net income |
1.65 | (0.69) | 1.54 | 0.99 | |
Capex/Depreciation |
(1.92) | (0.13) | (0.46) | (0.85) | |
Interest Coverage |
2.80 | (0.75) | 2.12 | 2.98 | |
Research and Development Expense of Revenue |
5.24% | 6.04% | 6.37% | 5.78% | |
Selling, General and Administrative Expense of Revenue |
25.91% | 28.73% | 29.04% | 27.86% | |
Intangible Assets out of Total Assets |
0.44 | 0.41 | 0.40 | 0.40 | |
Share Based Compensation of Revenue |
1.50% | 0.46% | 1.30% | 1.60% | |
Graham Net Nets |
(2.86) | (4.17) | (4.59) | (1.99) | |
Graham Number |
12.30 | 6.85 | 8.56 | 8.25 | |
Earnings Yield |
18.07% | 10.04% | 15.69% | 5.83% | |
Free Cash Flow Yield |
22.47% | 22.30% | 35.91% | 13.05% | |
Revenue per Share |
6.16 | 5.81 | 5.61 | 5.93 | |
Operating CF per Share |
1.02 | 0.54 | 0.86 | 0.41 | |
Capex per Share |
(0.44) | (0.17) | (0.14) | (0.29) | |
Free Cash Flow per Share |
0.57 | 0.37 | 0.72 | 0.12 | |
Cash per Share |
2.58 | 2.21 | 4.29 | 4.31 | |
Shareholders Equity per Share |
3.49 | 2.90 | 3.47 | 3.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.49 | 2.90 | 3.47 | 3.83 | |
Free Cash Flow |
149.00 | 96.00 | 188.00 | 31.00 | |
Working Capital |
2,021.00 | 1,962.00 | 2,432.00 | 2,495.00 | |
Capital Expenditures |
(115.00) | (45.00) | (37.00) | (76.00) | |
Net Current Asset Value |
(7,946.00) | (7,763.00) | (7,161.00) | (7,061.00) | |
EV/EBIT |
9.09 | 12.05 | 10.91 | 13.32 | |
Capex to Sales |
0.07 | 0.03 | 0.03 | 0.05 | |
Price to Operating Income |
2.31 | 2.26 | 1.89 | 4.32 | |
| Other line items | |||||
Average Receivables |
1,584.50 | 1,344.50 | 1,420.50 | 1,488.00 | |
Average Payables |
1,083.00 | 1,052.50 | 994.50 | 1,059.00 | |
Average Inventory |
1,435.50 | 1,363.50 | 1,367.50 | 1,402.50 | |
Average Assets |
13,152.00 | 12,984.00 | 13,076.00 | 13,339.00 | |
Average Common Equity |
699.50 | 612.00 | 722.50 | 869.50 |
Columns are period end dates